The Use of Androgen Priming in Women with Reduced Ovarian Reserve Undergoing Assisted Reproductive Technology

Alison Richardson; Kanna Jayaprakasan

doi:10.1055/s-0041-1735646

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2021; 39(05/06): 207-219
DOI: 10.1055/s-0041-1735646

Review Article

The Use of Androgen Priming in Women with Reduced Ovarian Reserve Undergoing Assisted Reproductive Technology

Authors

Alison Richardson

¹Department of Reproductive Medicine and Surgery, University Hospitals of Leicester NHS Trust, Leicester Fertility Centre, Infirmary Square, Leicester, United Kingdom
Kanna Jayaprakasan

²Department of Reproductive Medicine and Surgery, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, United Kingdom

³CARE Fertility Nottingham, Nottingham Business Park, Nottingham, United Kingdom

Abstract

Androgen priming with either dehydroepiandrosterone (DHEA) or testosterone has been suggested as an adjunct to improve in vitro fertilization (IVF) outcomes in women with diminished ovarian reserve (DOR). Numerous studies have investigated the effects of both DHEA and testosterone on IVF outcome. The results were inconsistent, and the quality of most studies is substandard. Meta-analyses have consistently reported that DHEA does appear to significantly improve IVF outcome in women with predicted or proven poor ovarian response (POR), but these have included some normal responders and/or nonrandomized studies. Our meta-analyses including randomized controlled trials (RCTs) incorporating only women with DOR or POR suggest that DHEA confers no benefit. While meta-analyses of RCTs on the use of testosterone in women with DOR or POR showed an improved IVF outcome, most studies included are of low quality with high risk of bias. When analysis of data from studies of only low-risk bias was performed, such a benefit with testosterone was not observed. Although recruitment may well be a challenge, a large, well-designed RCT is, however, still warranted to investigate whether or not androgen priming with either DHEA or testosterone should be recommended as an adjuvant treatment for women with DOR or POR undergoing IVF.

Keywords

DHEA - testosterone - ovarian response - poor responders - IVF - clinical pregnancy

Full Text

References

References
1 Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 2004; 19 (07) 1612-1617
2 Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proc R Soc Lond B Biol Sci 1963; 158: 417-433
3 Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat (Basel) 1952; 14 (1-2): 108-123
4 Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65 (06) 1231-1237
5 Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 1996; 11 (07) 1484-1486
6 Baird DT, Collins J, Egozcue J. et al; ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005; 11 (03) 261-276
7 Padilla SL, Garcia JE. Effect of maternal age and number of in vitro fertilization procedures on pregnancy outcome. Fertil Steril 1989; 52 (02) 270-273
8 Ubaldi FM, Cimadomo D, Vaiarelli A. et al. Advanced maternal age in IVF: still a challenge? The present and the future of its treatment. Front Endocrinol (Lausanne) 2019; 10: 94
9 Yeung T, Chai J, Li R, Lee V, Ho PC, Ng E. A double-blind randomised controlled trial on the effect of dehydroepiandrosterone on ovarian reserve markers, ovarian response and number of oocytes in anticipated normal ovarian responders. BJOG 2016; 123 (07) 1097-1105
10 Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000; 73 (04) 667-676
11 Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2010; (01) CD004379
12 Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel?. Fertil Steril 2011; 96 (05) 1058-61.e7
13 NICE. Fertility problems: assessment and treatment. [CG156], 2017. Accessed August 20, 2021 at: https://www.nice.org.uk/guidance/cg156
14 Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26 (07) 1616-1624
15 Løssl K, Freiesleben NC, Wissing ML. et al. Biological and clinical rationale for androgen priming in ovarian stimulation. Front Endocrinol (Lausanne) 2020; 11: 627
16 Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010; 24 (07) 1393-1403
17 Walters KA, Simanainen U, Handelsman DJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010; 16 (05) 543-558
18 Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 101 (12) 2622-2629
19 Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999; 84 (08) 2951-2956
20 Weil SJ, Vendola K, Zhou J. et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1998; 83 (07) 2479-2485
21 Rice S, Ojha K, Whitehead S, Mason H. Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries. J Clin Endocrinol Metab 2007; 92 (03) 1034-1040
22 Jeppesen JV, Kristensen SG, Nielsen ME. et al. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab 2012; 97 (08) E1524-E1531
23 Saunders PT, Millar MR, Williams K. et al. Differential expression of estrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod 2000; 63 (04) 1098-1105
24 Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17 (02) 121-155
25 Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol 2003; 21 (05) 346-355
26 Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78 (06) 1360-1367
27 Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000; 15 (10) 2129-2132
28 Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006; 21 (11) 2845-2849
29 Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007; 24 (12) 629-634
30 Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011; 9: 67
31 Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 2009; 7: 108
32 Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015; (11) CD009749
33 Nardo LG, El-Toukhy T, Stewart J, Balen AH, Potdar N. British Fertility Society Policy and Practice Committee. British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for good clinical practice. Hum Fertil (Camb) 2015; 18 (01) 2-15
34 Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. J Clin Endocrinol Metab 1968; 28 (03) 355-358
35 Horie K, Takakura K, Fujiwara H, Suginami H, Liao S, Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum Reprod 1992; 7 (02) 184-190
36 Garcia-Velasco JA, Moreno L, Pacheco A. et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84 (01) 82-87
37 Nielsen ME, Rasmussen IA, Kristensen SG. et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011; 17 (01) 63-70
38 Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999; 61 (02) 353-357
39 Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 2001; 76 (02) 241-248
40 Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil Steril 2009; 91 (02) 644-646
41 Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol 2009; 21 (04) 306-308
42 Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?. Reprod Biol Endocrinol 2011; 9: 116
43 Ménézo Y, Dale B, Cohen M. DNA damage and repair in human oocytes and embryos: a review. Zygote 2010; 18 (04) 357-365
44 Pitteloud N, Mootha VK, Dwyer AA. et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28 (07) 1636-1642
45 Triantafyllidou O, Sigalos G, Vlahos N. Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. Hum Fertil (Camb) 2017; 20 (02) 80-87
46 Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol 2013; 29 (10) 940-943
47 Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 2010; 8: 140
48 Sönmezer M, Ozmen B, Cil AP. et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online 2009; 19 (04) 508-513
49 Jirge PR, Chougule SM, Gavali VG, Bhomkar DA. Impact of dehydroepiandrosterone on clinical outcome in poor responders: a pilot study in women undergoing in vitro fertilization, using bologna criteria. J Hum Reprod Sci 2014; 7 (03) 175-180
50 Singh N, Zangmo R, Kumar S. et al. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. Gynecol Endocrinol 2013; 29 (11) 989-992
51 Zangmo R, Singh N, Kumar S, Vanamail P, Tiwari A. Role of dehydroepiandrosterone in improving oocyte and embryo quality in IVF cycles. Reprod Biomed Online 2014; 28 (06) 743-747
52 Vlahos N, Papalouka M, Triantafyllidou O. et al. Dehydroepiandrosterone administration before IVF in poor responders: a prospective cohort study. Reprod Biomed Online 2015; 30 (02) 191-196
53 Weissman A, Horowitz E, Ravhon A, Golan A, Levran D. Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol Endocrinol 2011; 27 (12) 1014-1017
54 Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25 (10) 2496-2500
55 Artini PG, Simi G, Ruggiero M. et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol Endocrinol 2012; 28 (09) 669-673
56 Moawad M, Shaeer M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fertil Soc J 2012; 17 (04) 268-274
57 Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. Eur J Obstet Gynecol Reprod Biol 2014; 173: 63-65
58 Yeung TW, Chai J, Li RH, Lee VC, Ho PC, Ng EH. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014; 102 (01) 108-115.e1
59 Zhang HH, Xu PY, Wu J. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J Ovarian Res 2014; 7: 93
60 Kotb MM, Hassan AM, AwadAllah AM. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2016; 200: 11-15
61 Narkwichean A, Maalouf W, Baumgarten M. et al. Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial. Eur J Obstet Gynecol Reprod Biol 2017; 218: 39-48
62 Tartagni M, Cicinelli MV, Baldini D. et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod Biol Endocrinol 2015; 13: 18
63 Tartagni M, De Pergola G, Damiani GR. et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol 2015; 67 (01) 7-12
64 Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab 2013; 98 (01) 380-388
65 Divita AE, Kanzepolsky LS, Notrica JA. et al. Does dehidroepiandrosterone sulfate (DHEAS) co- treatment improve art outcome? A prospective, randomized, double-blind placebo-controlled trial. Fertil Steril 2003; 80: S111-S112
66 Evans JA. A randomised, double blinded, placebo controlled, single centre trial comparing dehydroepiandrosterone (DHEA) and placebo in the treatment of women with resistant ovaries prior to in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI). BJOG 2013; 93: 225
67 Jindal A, Singh R. A prospective randomised controlled study on the role of dehydroepiandrosterone (DHEA) on improving ovarian response in known poor responders in previous failed IVF-ICSI cycles. Hum Reprod 2014; 29: i14
68 Li J, Yuan H, Chen Y, Wu H, Wu H, Li L. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. Int J Gynaecol Obstet 2015; 131 (03) 240-245
69 Schwarze JE, Canales J, Crosby J, Ortega-Hrepich C, Villa S, Pommer R. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: a systematic review and meta-analysis. JBRA Assist Reprod 2018; 22 (04) 369-374
70 Liu Y, Hu L, Fan L, Wang F. Efficacy of dehydroepiandrosterone (DHEA) supplementation for in vitro fertilization and embryo transfer cycles: a systematic review and meta-analysis. Gynecol Endocrinol 2018; 34 (03) 178-183
71 Xu L, Hu C, Liu Q, Li Y. The effect of dehydroepiandrosterone (DHEA) supplementation on IVF or ICSI: a meta-analysis of randomized controlled trials. Geburtshilfe Frauenheilkd 2019; 79 (07) 705-712
72 Zhang Y, Zhang C, Shu J. et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update 2020; 26 (02) 247-263
73 Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP, Hugues JN. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique–a prospective, randomized, double-blind study. Hum Reprod 2006; 21 (05) 1204-1211
74 Fábregues F, Peñarrubia J, Creus M. et al. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod 2009; 24 (02) 349-359
75 Kim CH, Howles CM, Lee HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011; 95 (02) 679-683
76 Kim CH, Ahn JW, Moon JW, Kim SH, Chae HD, Kang BM. Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF outcomes in poor responders. Dev Reprod 2014; 18 (03) 145-152
77 Bosdou JK, Venetis CA, Dafopoulos K. et al. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum Reprod 2016; 31 (05) 977-985
78 Saharkhiz N, Zademodares S, Salehpour S, Hosseini S, Nazari L, Tehrani HG. The effect of testosterone gel on fertility outcomes in women with a poor response in in vitro fertilization cycles: a pilot randomized clinical trial. J Res Med Sci 2018; 23: 3
79 Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007; 13 (03) 239-248
80 van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2002; 3 (01) 23-31
81 Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; (04) CD004509
82 Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother 2000; 34 (12) 1419-1422
83 Labrie F, Luu-The V, Labrie C. et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24 (02) 152-182
84 Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17 (10) 2573-2579
85 Bosch E, Broer S, Griesinger G. et al; ESHRE Guideline Group on Ovarian Stimulation. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020; 2020 (04) a067
86 Zhang H, Chu Y, Zhou P. et al. Dehydroepiandrosterone plus climen supplementation shows better effects than dehydroepiandrosterone alone on infertility patients with diminished ovarian reserve of low-FSH level undergoing in-vitro fertilization cycles: a randomized controlled trial. Reprod Biol Endocrinol 2016; 14: 9
87 Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsbøll S, Andersen AN. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod 2008; 23 (08) 1820-1829
88 Durnerin CI, Erb K, Fleming R. et al; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008; 23 (02) 421-426
89 Bercaire L, Nogueira SM, Lima PC. et al. ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation. JBRA Assist Reprod 2018; 22 (01) 52-55
90 Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH, Andersen AN. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod 2012; 27 (10) 3074-3084
91 Smitz J, Andersen AN, Devroey P, Arce JC. MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007; 22 (03) 676-687
92 Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev 2017; 11: CD008528